Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.376
S. Barbadillo, V. Martínez Callejo, M. Ochagavía Sufrategui, A. García-Avello Fernández-Cueto, MV Villacañas Palomares, VS Carmen Maria, M. Martín López, M. Valero Domínguez
{"title":"2SPD-003 Telepharmacy in onco-haematologic patients: a 7-month experience","authors":"S. Barbadillo, V. Martínez Callejo, M. Ochagavía Sufrategui, A. García-Avello Fernández-Cueto, MV Villacañas Palomares, VS Carmen Maria, M. Martín López, M. Valero Domínguez","doi":"10.1136/ejhpharm-2022-eahp.376","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.376","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"54 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116040462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.377
R. Tamayo Bermejo, JC del Río Valencia, B. Mora Rodríguez, I. Muñoz Castillo
{"title":"2SPD-012 Immunotherapy in patients with non-small cell lung cancer: effectiveness and safety in real life","authors":"R. Tamayo Bermejo, JC del Río Valencia, B. Mora Rodríguez, I. Muñoz Castillo","doi":"10.1136/ejhpharm-2022-eahp.377","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.377","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131214907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.413
J. Pedreira Bouzas, EM García Rebolledo, C. Puivecino Moreno, M. García Gil
Background and importance Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a poor prognosis. Nintedanib and pirfenidone are the only drugs indicated for this path-ology. In pivotal clinical trials these drugs reduced the decline in forced vital capacity (FVC), which is consistent with a slowing of disease progression. and objectives Evaluation of the effectiveness and safety of nintedanib and pirfenidone in IPF in a second-level hospital.
{"title":"4CPS-257 Effectiveness and safety of nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis","authors":"J. Pedreira Bouzas, EM García Rebolledo, C. Puivecino Moreno, M. García Gil","doi":"10.1136/ejhpharm-2022-eahp.413","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.413","url":null,"abstract":"Background and importance Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a poor prognosis. Nintedanib and pirfenidone are the only drugs indicated for this path-ology. In pivotal clinical trials these drugs reduced the decline in forced vital capacity (FVC), which is consistent with a slowing of disease progression. and objectives Evaluation of the effectiveness and safety of nintedanib and pirfenidone in IPF in a second-level hospital.","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"119 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131419359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.405
C. Martinez-Molina, N. Pages, P. Riera, A. Riera, H. Codes, C. Díaz-Torné, H. Corominas, J. Ruiz-Ramos, M. Masip
{"title":"4CPS-215 Persistence and therapeutic adherence to first-generation Janus kinase inhibitors in rheumatoid arthritis patients","authors":"C. Martinez-Molina, N. Pages, P. Riera, A. Riera, H. Codes, C. Díaz-Torné, H. Corominas, J. Ruiz-Ramos, M. Masip","doi":"10.1136/ejhpharm-2022-eahp.405","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.405","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130084291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.398
A. Aguado Paredes, M. Romero González, J. Cordero Ramos, M. Beltrán García
{"title":"4CPS-140 Antimicrobial stewardship programme in oncology patients through a multidisciplinary team","authors":"A. Aguado Paredes, M. Romero González, J. Cordero Ramos, M. Beltrán García","doi":"10.1136/ejhpharm-2022-eahp.398","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.398","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133128442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.383
R. Tamayo Bermejo, JC del Río Valencia, B. Mora Rodríguez, I. Muñoz Castillo
{"title":"4CPS-029 Pembrolizumab, nivolumab and atezolizumab: incremental cost-effectiveness ratio","authors":"R. Tamayo Bermejo, JC del Río Valencia, B. Mora Rodríguez, I. Muñoz Castillo","doi":"10.1136/ejhpharm-2022-eahp.383","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.383","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"301 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124297759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：